These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 11765303

  • 41. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
    Falk RH, Pollak A, Singh SN, Friedrich T.
    J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
    [Abstract] [Full Text] [Related]

  • 42. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS, Zehender M.
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [Abstract] [Full Text] [Related]

  • 43. The role of amiodarone in recent-onset atrial fibrillation after ibutilide has failed to restore sinus rhythm.
    Sideris S, Bonios M, Melexopoulou C, Exarchos P, Tsatiris K, Kogias J.
    Cardiology; 2007 May; 107(4):399-401. PubMed ID: 17284902
    [Abstract] [Full Text] [Related]

  • 44. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
    Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB.
    Circulation; 2000 Nov 07; 102(19):2385-90. PubMed ID: 11067793
    [Abstract] [Full Text] [Related]

  • 45. Comparison of class I and class III action in atrial fibrillation.
    Edvardsson N.
    Eur Heart J; 1993 Nov 07; 14 Suppl H():62-6. PubMed ID: 7904938
    [Abstract] [Full Text] [Related]

  • 46. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN.
    Am J Cardiol; 1996 Aug 29; 78(4A):17-27. PubMed ID: 8780325
    [Abstract] [Full Text] [Related]

  • 47. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]).
    Singh SN, Singh BN, Reda DJ, Fye CL, Ezekowitz MD, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD, Antman EM, Falk RH, Lopez B, Tang XC.
    Am J Cardiol; 2003 Aug 15; 92(4):468-72. PubMed ID: 12914883
    [Abstract] [Full Text] [Related]

  • 48. A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?
    Wolbrette DL, Hussain S, Maraj I, Naccarelli GV.
    J Cardiovasc Pharmacol Ther; 2019 Jan 15; 24(1):3-10. PubMed ID: 29940780
    [Abstract] [Full Text] [Related]

  • 49. Atrial fibrillation: choosing an antiarrhythmic drug.
    Rudo T, Kowey P.
    Curr Cardiol Rep; 2006 Sep 15; 8(5):370-6. PubMed ID: 16956453
    [Abstract] [Full Text] [Related]

  • 50. Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation.
    Agusala K, Oesterle A, Kulkarni C, Caprio T, Subacius H, Passman R.
    Pacing Clin Electrophysiol; 2015 Apr 15; 38(4):490-8. PubMed ID: 25626340
    [Abstract] [Full Text] [Related]

  • 51. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH, Decara JM.
    Am Heart J; 2000 Nov 15; 140(5):697-706. PubMed ID: 11054613
    [Abstract] [Full Text] [Related]

  • 52. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence.
    Slavik RS, Tisdale JE, Borzak S.
    Prog Cardiovasc Dis; 2001 Nov 15; 44(2):121-52. PubMed ID: 11568824
    [Abstract] [Full Text] [Related]

  • 53. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone.
    Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S.
    Circulation; 2003 Mar 18; 107(10):1440-6. PubMed ID: 12642367
    [Abstract] [Full Text] [Related]

  • 54. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned.
    Vijayalakshmi K, Whittaker VJ, Sutton A, Campbell P, Wright RA, Hall JA, Harcombe AA, Linker NJ, Stewart MJ, Davies A, de Belder MA.
    Am Heart J; 2006 Apr 18; 151(4):863.e1-6. PubMed ID: 16569550
    [Abstract] [Full Text] [Related]

  • 55. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.
    Singh S.
    J Interv Card Electrophysiol; 2004 Apr 18; 10 Suppl 1():71-6. PubMed ID: 14739742
    [Abstract] [Full Text] [Related]

  • 56. Efficacy of sequential antiarrhythmic treatment in sinus rhythm maintenance after successful electrocardioversion in patients with chronic non-valvular atrial fibrillation.
    Kosior D, Opolski G, Torbicki A.
    Med Sci Monit; 2001 Apr 18; 7(1):68-73. PubMed ID: 11208496
    [Abstract] [Full Text] [Related]

  • 57. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM, Verma A, Talajic M, Nattel S, Dorian P, CCS Atrial Fibrillation Guidelines Committee.
    Can J Cardiol; 2011 Apr 18; 27(1):47-59. PubMed ID: 21329862
    [Abstract] [Full Text] [Related]

  • 58. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial.
    Singh SN, Tang XC, Reda D, Singh BN.
    Heart Rhythm; 2009 Feb 18; 6(2):152-5. PubMed ID: 19187902
    [Abstract] [Full Text] [Related]

  • 59. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B, Pedersen O, Torp-Pedersen C, Sahebzadah N, Køber L.
    Drug Saf; 2002 Feb 18; 25(12):847-65. PubMed ID: 12241126
    [Abstract] [Full Text] [Related]

  • 60. Is either sotalol or amiodarone more effective than digoxin for converting patients with new-onset atrial fibrillation (AF) to sinus rhythm within 48 hours?
    Forney AJ, Schooff M.
    J Fam Pract; 2000 Nov 18; 49(11):982. PubMed ID: 11093561
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.